---
title: "Giant Biogene Announces Special 2025 Dividend, Signaling Confidence in Cash Position"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279774673.md"
description: "Giant Biogene Holding Co. Ltd. has announced a special cash dividend of RMB 0.6714 per share for the financial year ending December 31, 2025, reflecting management's confidence in its cash position. The dividend, pending shareholder approval on May 28, 2026, will be paid in Hong Kong dollars on June 25, 2026. This decision aims to reward shareholders while maintaining financial flexibility. The company's stock (HK:2367) currently holds a Buy rating with a price target of HK$36.00, appealing to income-focused investors in the biotech sector."
datetime: "2026-03-19T11:11:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279774673.md)
  - [en](https://longbridge.com/en/news/279774673.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279774673.md)
---

# Giant Biogene Announces Special 2025 Dividend, Signaling Confidence in Cash Position

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Giant Biogene Holding Co. Ltd. ( (HK:2367) ) has issued an announcement.

Giant Biogene Holding Co., Ltd. has declared a special cash dividend of RMB 0.6714 per share for the financial year ended 31 December 2025, underscoring management’s willingness to return excess capital to shareholders. The dividend, subject to shareholder approval on 28 May 2026, will be paid in Hong Kong dollars on 25 June 2026, with the ex-dividend date set for 1 June and the record date for 8 June, giving investors clear timelines to position around the payout.

The move signals confidence in the company’s cash generation and balance sheet strength, and may enhance its appeal to income-focused investors in the biotech space. By opting for a special dividend rather than a permanent increase in its regular payout, the company preserves financial flexibility while rewarding existing shareholders, which could support its valuation and trading liquidity around key dividend dates.

The most recent analyst rating on (HK:2367) stock is a Buy with a HK$36.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

**More about Giant Biogene Holding Co. Ltd.**

Giant Biogene Holding Co., Ltd. is a Hong Kong-listed company in the biotechnology and healthcare sector. It focuses on developing and commercializing biological products, with its shares traded on the Main Board of the Stock Exchange of Hong Kong under stock code 02367, targeting investors seeking exposure to China’s biopharmaceutical growth.

**Average Trading Volume:** 5,282,517

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$34.2B

For a thorough assessment of 2367 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [02367.HK](https://longbridge.com/en/quote/02367.HK.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Giant Biogene Sets 2026 AGM to Refresh Board Mandates and Appoint New Auditor](https://longbridge.com/en/news/285394236.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data](https://longbridge.com/en/news/286722721.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)